Demystifying COVID-19 : (Record no. 27431)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11074nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6640409 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724115135.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2021 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781681087788 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781681087795 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6640409 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6640409 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1257084780 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RA644.C67 K373 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.2414 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Karcioglu, Ozgur. |
| 245 10 - TITLE STATEMENT | |
| Title | Demystifying COVID-19 : |
| Remainder of title | Understanding the Disease, Its Diagnosis. and Treatment. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Sharjah : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2021. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (413 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- Contagion of the Pandemics: The Situation in the World -- FATALITY AND MORTALITY DIFFERENCES BETWEEN COUNTRIES -- WHICH COUNTRIES HAVE THE HIGHEST NUMBER OF CASES? -- TO NORMALIZE OR NOT TO NORMALIZE, IT IS THE MAIN QUESTION! -- CONTAGIOUSNESS OF CORONAVIRUS -- IN WHAT WAYS IS CORONAVIRUS TRANSMITTED? -- Where is The Contamination Happening? -- Is It Airborne? -- Air Conditioning + 1 Patient = 10 Patients: Who is Guilty? -- How is The Air Conditioner Cleaned? -- How Should We Clean Our Air Conditioner? -- CONCLUSION -- REFERENCES -- How Can a Country Defeat COVID-19? Value of R0, Rt and Re -- WHAT ARE R0, RT, AND RE? -- INCUBATION PERIOD -- PRINCIPLES OF SURVEILLANCE AND STRUGGLE WITH THE PANDEMIC: HOW COUNTRIES DIFFER FROM EACH OTHER? -- HOW EFFECTIVE IS HOME STAY, SOCIAL / INDIVIDUAL ISOLATION IN PREVENTING THE SPREAD OF COVID-19? -- BELGIUM HAS A VERY DIFFERENT CASE SITUATION -- HERD IMMUNITY AND THE 'SECOND WAVE' PROBLEM: MYTH OR TRUTH? -- IS THE 'ORDINARY CITIZEN' ALSO GUILTY? WHICH MISTAKES DID THEY DO IN THE PANDEMIC AND 'NORMALIZATION'? -- HOW DOES THIS DISEASE END? -- THE SPANISH FLU EXPERIENCES OF 1918: DOES HISTORY LIGHT OUR WAY? -- Why is It Called 'Spanish Flu'? -- Is It Different From Other Flu Syndromes? -- WHAT HAPPENED IN THE USA? -- Mass Graves Were Opened in The Usa in September 1918 Due To Massive Death Toll -- REFERENCES -- Comorbid Diseases and COVID-19: COPD, Smoking, Obesity, Diabetes, Cancer, and Kidney Failure -- THE RELATIONSHIP BETWEEN COVID-19 FATALITY RATE AND COMORBIDITIES -- PULMONARY DISEASES AND COVID-19 -- Could COVID-19 Infection also Cause COPD-AA? -- Are Patients with COPD or Asthma at High Risk for Contracting COVID-19?. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Are Patients with COPD at High Risk for Severe COVID-19 and Death? -- How are The Follow-up and Treatment of COPD and COPD-AA Cases During The Pandemics? -- Are Systemic Corticosteroids (CST) Used in COPD-AA During Pandemic? -- Are There Any Changes For Asthma Patients? -- How is an Asthma Attack Treated While Infected with COVID-19? -- Is the Use of Nebulizers Recommended in The Treatment of Asthma/COPD During The COVID-19 Outbreak? -- Does Smoking and COPD Development Alter Expression of ACE2 Receptors? -- Does Smoking Affect Clinical Course? -- Is Smoking also Effective in Influenza? -- Is COVID-19 More Severe in Smokers? -- What are The Key Findings of Systematic Reviews and Meta-analyzes with High Level of Evidence? -- What is "Smoker's Paradox" (SP), are There any Justifications? -- OBESITY AND COVID-19 -- Numerical Data showing the Relationship between Obesity and COVID-19 -- DIABETES AND COVID-19 -- In a Diabetic Patient Hospitalized in The COVID-19 Process, There will be 5 Essential Steps of Management -- CANCER AND COVID-19 -- Why are Cancer Patients More Disadvantaged in Terms of COVID-19? -- Are There any More Special Risk Groups among People with Cancer? -- Can Cancer be Diagnosed During The Pandemic Period, and can Interventions be Performed as Before? -- Are there Specific Difficulties in Diagnostic Interventions for COVID-19? -- Are There Specific Difficulties for Cancer Patients Regarding Care and Treatment? -- Is there any Difference Regarding the Psychological Conditions of Cancer Patients in this Period? -- THE RISK OF REACTIVE OR MAJOR DEPRESSION WILL BE FURTHER INCREASED -- What are the General Messages? -- RENAL FAILURE (RF), ACUTE KIDNEY INJURY (AKI) AND COVID-19 -- LUNG-KIDNEY AXIS (LKA): A NEW PATHWAY FOR KIDNEY DAMAGE? -- CONCLUSION -- REFERENCES -- Risks and Losses of Healthcare Workers in the Pandemic Era. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | PHENOMENA PROVEN TO INCREASE THE RISK OF COVID-19 TRANSMISSION IN HCW -- Is COVID-19 Risky for HCW? -- How much Risk COVID-19 Impose on HCW? -- HEADLINES FROM VARIOUS COUNTRIES -- THE SITUATION IN TURKEY -- SITUATIONS INCREASING THE RISK OF INFECTION TO HCW -- Findings -- Precautions and Measures -- Personal Protective Equipment -- Sequence of Control Measures -- Infection Protection and Control Measures -- Psychosocial Problems in HCW During The Pandemics -- What kind of Interventions can be Pursued to Support The Resilience and Mental Health of Frontline HCW During The Pandemic? -- IS THERE ANY GOOD NEWS TO CONVEY? -- CONCLUSION -- REFERENCES -- What Kind of Disease is this? Signs and Symptoms, Predictors of Clinical Course and Management -- DO PATIENTS WHO ARE DIAGNOSED NECESSARILY HAVE SYMPTOMS? -- ASYMPTOMATIC AND SYMPTOMATIC… IS THERE A 3RD WAY? -- Can A Mild-looking Patient Worsen Quickly? -- WHICH MARKERS CAN WE USE TO PREDICT CLINICAL WORSENING? -- RADIOLOGICAL CRITERIA -- TYPICAL CASE -- HOW ARE COVID AND COUGH RELATED? -- Cough In Terms of Contagiousness -- Pharmacological Methods To Relieve Cough -- GASTROINTESTINAL COMPLAINTS AND FINDINGS IN THE COURSE OF COVID-19 -- CORONA FACTS: WHICH IS CORRECT? -- CONCLUSION -- REFERENCES -- Diagnosis of COVID-19: Which Tests To Do? Laboratory and Radiological Adjuncts To Recognition -- LABORATORY TESTS -- Cytokines and Related Findings -- Laboratory Values Can Also Highlight The Stages of The Disease -- Do Antibody Tests Give Accurate Results In The Early Period After Infection? -- CHEST IMAGING - RADIOLOGICAL EXAMINATIONS -- Which Should We Choose? X-ray, CT, USG, or MR? -- CASE EXAMPLE AND TIME COURSE OF THE DISEASE -- CONCLUSION -- REFERENCES -- Cardiovascular Disease, Myocarditis, Infarctions, And COVID-19 -- KEY FINDINGS FROM DIFFERENT DATABASE STUDIES. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | ARE ETHNIC DIFFERENCES IMPORTANT FOR COVID-19? -- HT AND COVID-19 -- MYOCARDIAL INJURY SEVERITY AND MORTALITY -- How Much Myocardial Damage Occurs in COVID-19? -- In Whom Does Myocardial Damage Occur and How Do We Identify It? -- Any Pathological Finding? -- Global View of Myocardial Infarction (STEMI / NSTEMI) After COVID-19 -- Did The Pandemic Affect Heart Attacks? -- What Should Be Done? -- COVID-19 and Myocardial Damage, Myocarditis -- Fulminant Myocarditis (FM) -- Symptoms and Signs in Myocarditis -- Ancillary Studies -- THROMBOTIC EVENTS, BLEEDING, COAGULOPATHIES, AND COVID-19 -- Cytokine-Mediated Alveolar Inflammation Triggers the Formation Of Microthrombi In The Pulmonary Vasculature, Which Can Culminate Into Thrombi Or Embolism In Severe Cases -- Increased D-dimer, PT, aPTT, CRP, ESR, and PCT Levels Noted on Presentation were Found To Be Associated With Death In Covid-19 Patients (Al-Samkari et al., 2020) -- Additional Note: Mean Values Of Fibrinogen, Ferritin, Pct Are Also Higher In Patients With Thrombosis -- Pathological Mechanism -- CONCLUSION -- REFERENCES -- Gastrointestinal Signs and Symptoms in the Course of COVID-19 -- INTRODUCTION -- HOW IMPORTANT IS GIS IN THE PATHOPHYSIOLOGY OF THE VIRUS? -- Which GI Findings Do We Mention About? -- Children and GI Complaints -- Inflammatory Bowel Diseases (IBD) and COVID-19 -- Hepatic Damage and COVID-19 -- CONCLUSION -- REFERENCES -- Is Our Psychology Affected By the Pandemic? How? -- WHAT ARE STRESS REACTIONS? WHAT CAN WE DO? -- WHY ARE WE STRESSED DURING THIS PERIOD? -- ADVERSE EMOTIONAL, PHYSICAL, OR COGNITIVE RESPONSES THAT ARISE IN RESPONSE TO THE EFFECTS OF THE COVID-19 PANDEMIC INCLUDE -- COVID-19 and our Psychology: What do the Researchers Say? -- COVID-19 and Dealing with Stress -- Coping with Stress -- Awareness of Emotions -- Social Relations. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Try not to Disturb your Routine and Sleep Patterns -- Do Hobbies Work? -- What Does Physical Activity Bring us? -- Bias and Stigmatization -- CONCLUSION -- REFERENCES -- COVID-19 and Our Brain: What's New? -- INTRODUCTION -- HOW CAN COVID-19 AFFECT THE BRAIN AND NERVOUS SYSTEM? -- WHAT KIND OF DAMAGE DOES COVID-19 CAUSE IN THE BRAIN? -- WHAT KINDS OF NEUROLOGICAL SIGNS AND SYMPTOMS DO COVID-19 CAN BE EVIDENT? -- DOES IT HAVE LONG-TERM EFFECTS ON THE CNS? -- EFFECTS OF COVID-19 ON PEOPLE WITH NEUROLOGICAL DISORDERS -- DOES COVID-19 INCREASE THE RISK OF STROKE? -- MANY PATIENTS MENTION LOSS OF SMELL / TASTE -- IS THERE AN ASSOCIATION BETWEEN ANOSMIA AND RESPIRATORY FAILURE? -- DOES COVID-19 TRIGGER BRAIN TISSUE INFLAMMATION (ENCEPHALITIS)? -- WHAT ARE THE TREATMENT METHODS AFTER COVID-19 INFLICTS THE CNS? -- CONCLUSION -- REFERENCES -- COVID-19 Pneumonia and ARDS: The Real Killer? -- DEFINITION -- CLINICAL FEATURES -- DIAGNOSIS -- THE MOST COMMON CT FINDINGS ON PRESENTATION (ADAPTED FROM PAN ET AL, 2020) -- DIFFERENTIAL DIAGNOSES -- OTHER SITUATIONS TO BE DISTINGUISHED -- SERUM ANTIBODY DETECTION -- LABORATORY FINDINGS -- RISK FACTORS FOR SEVERE DISEASE -- ARDS -- Treatment of Pneumonia and ARDS -- Hypoxia Management in Severe and Critical COVID-19 Patient -- Specific Drug Treatments -- CONCLUSION -- REFERENCES -- Pregnancy, COVID-19, and Children: Dangerous Trio? -- WHAT ARE THE CHARACTERISTICS OF PREGNANT WOMEN WITH COVID-19? -- Should there be a Different Warning for Pregnant Healthcare Workers? -- Could the Pregnant Women with Covid-19 Transmit the Disease to the Baby? -- How is Protection from Covid-19 during Pregnancy? -- What are the General Treatment Methods in Pregnant Women? -- Are the Drugs used in the Treatment of Covid-19 Harmful during Pregnancy? -- Can the Woman with COVID-19 Breastfeed her Baby?. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Is there Anything to Pay Attention to After Birth?. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | COVID-19 (Disease). |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yeniocak, Selman. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hosseinzadeh, Mandana. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Karcioglu, Ozgur |
| Title | Demystifying COVID-19: Understanding the Disease, Its Diagnosis. and Treatment |
| Place, publisher, and date of publication | Sharjah : Bentham Science Publishers,c2021 |
| International Standard Book Number | 9781681087795 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6640409">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6640409</a> |
| Public note | Click to View |
No items available.